BlackRock Investment Management, LLC - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 22 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q2 2015. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
BlackRock Investment Management, LLC ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2016$60,000
-23.1%
26,521
-7.8%
0.00%
Q2 2016$78,000
-32.2%
28,756
-28.3%
0.00%
Q1 2016$115,000
-42.5%
40,097
-12.4%
0.00%
Q4 2015$200,000
-42.7%
45,7930.0%0.00%
Q3 2015$349,000
-31.7%
45,7930.0%0.00%
-100.0%
Q2 2015$511,00045,7930.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q2 2015
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 2,675,889$6,797,0005.97%
PERKINS CAPITAL MANAGEMENT INC 449,950$1,143,0000.89%
Diametric Capital, LP 116,754$297,0000.23%
Granahan Investment Management 924,300$2,348,0000.17%
Requisite Energy Fund I LP 100,000$254,0000.10%
Requisite Capital Management, LLC 100,000$254,0000.10%
B. Riley Wealth Advisors, Inc. 250,000$635,0000.09%
Kalos Management, Inc. 74,420$179,0000.09%
Crow Point Partners, LLC 65,475$164,0000.03%
ARDSLEY ADVISORY PARTNERS LP 35,000$89,0000.02%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders